+

WO1996040774A1 - Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques - Google Patents

Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques Download PDF

Info

Publication number
WO1996040774A1
WO1996040774A1 PCT/US1996/009773 US9609773W WO9640774A1 WO 1996040774 A1 WO1996040774 A1 WO 1996040774A1 US 9609773 W US9609773 W US 9609773W WO 9640774 A1 WO9640774 A1 WO 9640774A1
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
receptor
complex
subunit
signalling
Prior art date
Application number
PCT/US1996/009773
Other languages
English (en)
Inventor
Jeffrey L. Browning
Werner Meier
Michael N. Karpusas
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Priority to AU61663/96A priority Critical patent/AU6166396A/en
Publication of WO1996040774A1 publication Critical patent/WO1996040774A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Definitions

  • This invention relates to lymphotoxin (LT) complexes comprising lymphotoxin- ⁇ (LT-c and lymphotoxin- ⁇ (LT- ⁇ ) subunits, and modified versions thereof, which can act as specific inhibitors of the biological events mediated by the ligands and receptors of the tumor necrosis factor (TNF) family.
  • This invention also relates to unique portions of the LT- ⁇ and LT- ⁇ protein sequences, "LT subunit association domains", which potentiate subunit assembly into an active trimeric ligand.
  • This invention provides TNF- related ligand monomers mutated in their respective subunit association domains which permits them to form heteromeric complexes with LT subunits.
  • Altered ligands which have only one functional receptor binding site per heteromer can inhibit signalling by that receptor.
  • mutant and chimeric LT subunits with can alter the receptor binding properties of heteromeric complexes assembled from them.
  • Polypeptides comprising LT subunit association domains, LT heteromeric complexes which inhibit receptor signalling, pharmaceutical compositions comprising LT heteromeric inhibitors, and methods for treatment using those pharmaceutical compositions are also provided.
  • Tumor Necrosis Factor TNF
  • TNF Tumor Necrosis Factor
  • a parallel family of TNF-related receptors react with these molecules and trigger a variety of pathways including cell death, cell proliferation, tissue differentiation and proinflammatory responses.
  • TNF TNF-receptor pairs
  • L: :R include: TNF::TNF-R, LT- ⁇ : .-TNF-R, LT- ⁇ / ⁇ : :LT- ⁇ -R, FasL::Fas, CD40L: :CD40R, CD30L::CD30, CD27L::CD27, Ox40L: :Ox40 and 4-1BBL: :4-lBB.
  • TNF and LT- ⁇ are cytokines with an extraordinary range of activities mediated by TNF receptor activation.
  • TNF-R TNF and LT- ⁇ specific receptors
  • p55 or p60
  • p75 or p80
  • TNF-R activation is associated with immune and inflammatory reactions, septic shock, autoimmune disorders and graft-host disease (Beutler, B., Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. New York: Raven Press (1994)) . It would be useful in many instances to treat the reactions and disorders associated with TNF-R by selectively inhibiting TNF-R signalling.
  • a third receptor binds LT heteromeric complexes (predominantly LT- ⁇ l/ ⁇ 2 and LT- ⁇ 2/ ⁇ l) but does not bind TNF or LT- ⁇ (Crowe et al. , Science. 264, pp. 707-10 (1994)) .
  • This third receptor is called herein the LT- ⁇ receptor ("LT- ⁇ -R") .
  • LT- ⁇ -R signalling may play a role in peripheral lymphoid organ development, and may also play a role in humoral immune responses. The ability to selectively block the LT- ⁇ - R pathway would also be useful.
  • FasL Another member of the TNF superfamily is the FasL: :Fas complex.
  • Signalling through the Fas pathway also has pleiotropic effects. Activated Fas can kill cells by triggering apoptosis — programmed cell death.
  • the Fas pathway represents a major mechanism for cytolytic T lymphocyte killing (Lowin et al . Nature. 370, pp. 650-52 (1994); Koji a et al. Immunity, 1, pp. 357-64 (1994)) .
  • Fas signalling is involved in apoptosis of chronically- activated mature T cells, and suggest a role for Fas signalling in peripheral tolerance (Russel and Wang, Eur. J. Immunol.. 23, pp.
  • Fas-induced cell death may also a major component of graft rejection.
  • Inhibitors of the Fas pathway may be useful in modulating activated T cell apoptosis and in reducing tissue rejection following organ transplantation.
  • signalling through the Fas receptor is thought to be involved in liver necrosis during fulminant hepatitis (J. Ogasawara et al., Nature. 364, pp. 806-80, (1993)) .
  • Inhibitors of the Fas pathway may also be useful in blocking HIV- induced lymphocyte depletion (Katsikis et al. , J. Exp. Med.. 181, pp. 2029-36 (1995)) . The ability to block this signalling pathway would be beneficial in such instances.
  • CD40R on an immature B cell binds to CD40L on the surface of an activated CD4 + helper T cell
  • CD40 signalling stimulates the B cell to undergo Ig isotype switching and to secrete mature Igs.
  • B cells proliferate and mature into memory and antibody- secreting cells. This role for CD40R signalling has been confirmed in humans. Patients who harbor mutations in their CD40L gene can make only IgM antibodies and are severely immunodeficient (Callard et al., Immunol. Today. 564, pp. 559-64 (1993)) .
  • inhibitors of the CD40 signalling pathway could be useful in suppressing undesirable B cell proliferation and isotype switching.
  • inhibitors of the mouse CD40 pathway block antibody responses and autoimmune disease development in mice (Durie, F. H. et al. , Science. 261, pp. 1328-133 (1993)), and HIV proliferation in vitro (Pinchuk et al., Immunity. 1, p. 317 (1994)) .
  • TNF family members including CD27, CD30, 4-1BB and OX-40, appear to play roles in T cell proliferation and cytokine regulation.
  • 4-1BB pathway plays a role in costimulation of IL-2 production and in inducing T cell proliferation (DeBenedette et al., J. Exp. Med.. 181, pp. 985-92 (1995)) .
  • the OX-40 cell surface antigen is a marker of activated CD4+ T cells that acts as a costimulatory receptor of CD4+ T cell proliferation (W.R. Godfrey et al. , J. Exp. Med.. 180, pp. 757-62 (1994) ) .
  • TNF-R signalling is activated through the close spatial aggregation of multiple receptors on the cell surface, a process interchangeably called "receptor clustering" or "receptor cross-linking".
  • receptor clustering is mediated by its specificity for multivalent ligands -- TNF or LT- ⁇ 3. Each trimeric ligand binds to and clusters up to three TNF-R molecules.
  • TNF-R clustering and activation can also be induced using receptor-specific antibodies (Engelmann et al. , J. Biol . Chem.. 265, pp. 14497-504 (1990)) . Fas (Ogasawara et al. , Nature. 364, pp. 806- 809 (1993)) and LT- ⁇ -R signalling (applicants' co- pending United States application Serial No. 08/378,968) can also be activated by receptor cross- linking using appropriate receptor-specific antibodies.
  • TNF-R TNF-R
  • LT- ⁇ -R Fas, CD40R
  • TNF-like receptors TNF-like receptors
  • One way to achieve selective inhibition would be to modify TNF or a TNF-like ligand so that it could bind to its cognate receptor but could not cluster adjacent receptors.
  • a TNF-related multivalent ligand altered to bind only one surface receptor molecule would inhibit receptor signalling by blocking aggregation of adjacent surface receptor molecules.
  • LT- ⁇ /LT- ⁇ heteromeric ligands constitute such inhibitors and form the basis of this invention.
  • lymphotoxin complexes formed between LT- ⁇ and LT- ⁇ subunits are provided ("LT- ⁇ / ⁇ heteromeric complexes") which inhibit TNF-R signalling.
  • Preferred compositions and methods of this embodiment comprise soluble LT- ⁇ 2/ ⁇ l trimers .
  • defined residues of the LT subunits are mutated to eliminate any low level binding activity to LT- ⁇ -R, and if desired, to increase the relative binding affinity of the LT heterotrimer for either p55 or p75 TNF-R.
  • compositions and methods of this embodiment comprise soluble LT- ⁇ l/ ⁇ 2 trimers, and soluble LT- ⁇ 2/ ⁇ l trimers which are mutated at defined residues within LT- ⁇ -containing clefts to reduce or eliminate binding to TNF-R.
  • the altered LT- ⁇ 2/ ⁇ l heterotrimer is a specific inhibitor of LT- ⁇ -R signalling.
  • LT trimeric scaffold structure is used as a base from which other TNF-like ligand receptor binding domains are displayed to make a chimeric LT inhibitor with altered receptor binding characteristics .
  • residues in the LT- ⁇ / ⁇ cleft of a soluble LT- ⁇ 2/ ⁇ l trimer required for TNF-R binding are exchanged with a corresponding portion of the receptor binding domain of a heterologous TNF-like ligand to target the soluble trimeric inhibitor to that other TNF-like receptor.
  • similar changes are made to residues in the LT- ⁇ / ⁇ cleft of a soluble LT- ⁇ l/ ⁇ 2 trimer to convert that cleft into a receptor binding site of a different TNF- like receptor.
  • mutations which reduce background binding of the soluble chimeric LT inhibitors to LT or TNF receptors are also incorporated. Pharmaceutical compositions and methods using these complexes are provided.
  • an inhibitor of a TNF-like receptor is made by altering a corresponding TNF-like ligand subunit in its subunit association domain so that it can form mixed heterotrimers with LT subunits .
  • a trimeric inhibitor of a TNF-like receptor is formed by changing residues of the TNF-like subunit association domain to more closely resemble those of an LT subunit association domain.
  • a LT subunit association domain is grafted onto a TNF-like ligand subunit (or variant or portion thereof) comprising a receptor binding domain in a position which does not significantly disrupt the ability of the TNF-l ⁇ ke receptor binding domain to interact with its cognate receptor.
  • Figure 2 Purification schemes: various combinations of TNF or LT receptor affinity columns can be used to purify LT- ⁇ l/ ⁇ 2 and LT- ⁇ 2/ ⁇ l.
  • Figure 3. Analysis of individual LT multimer fractions analyzed by C4 reverse phase HPLC show the relative ratios of LT- ⁇ and LT- ⁇ in each preparation.
  • Figure 4a Gel exclusion sizing analysis of the LT trimers purified with receptor affinity columns. Pure proteins were analyzed on a TSK 3000 HPLC resin in a phosphate buffered saline buffer.
  • FIG 4b Ion exchange chromatographic analysis of the LT trimers purified with receptor affinity columns.
  • Figure 5a BiacoreTM sensorgrams of the binding of LT- ⁇ 3, LT- ⁇ 2/ ⁇ l and LT- ⁇ l/ ⁇ 2 to the p55 TNF receptor as a function of time. Various concentrations of the ligand are flowed across a BiacoreTM chip and the association and dissociation phases of ligand binding are monitored.
  • Figure 5b BiacoreTM sensorgrams of the binding of LT- ⁇ 3, LT- ⁇ 2/ ⁇ l and LT- ⁇ l/ ⁇ 2 to the LT- ⁇ receptor as a function of time, as described in Figure 5a.
  • Figure 5b shows that both LT- ⁇ 2/ ⁇ l and LT- ⁇ l/ ⁇ 2 bind well to LT- ⁇ -R, but that LT- ⁇ 2/ ⁇ l comes off more quickly than LT- ⁇ l/ ⁇ 2 and thus has a lower affinity for LT- ⁇ -R.
  • Figure 6. Ability of soluble LT- ⁇ 2/ ⁇ l complexes to block the anti-proliferative activity of TNF on: (a) a mouse indicator line L929, (b) a human cervical carcinoma ME180 in the presence of IFN- ⁇ , and (c) a human colon carcinoma HT29 in the presence of IFN- ⁇ . In each case the concentration of LT- ⁇ 2/ ⁇ l is varied in the presence or absence of 1 ng/ml r-hu-TNF.
  • the dashed lines indicate the absorbance values obtained for cells grown in the absence of TNF (top dashed line) or the presence of 1 ng/ml TNF (bottom dashed line) .
  • Figure 7. Ability of soluble LT- ⁇ l/ ⁇ 2 and LT- ⁇ 2/ ⁇ l to block the binding of a soluble form of the LT- ⁇ -R to the LT- ⁇ / ⁇ ligand on a cell surface thus mimicking how a LT- ⁇ l/ ⁇ 2 complex would block LT- ⁇ -R signalling.
  • LT- ⁇ l/ ⁇ 2 or LT- ⁇ 2/ ⁇ l were added to PMA-activated 11-23 cells and then soluble LT- ⁇ -R-Fc was allowed to bind to the surface ligand.
  • Bound human Fc was quantitated using anti-human IgG-phycoerythrin labelled antibodies and FACS analysis was performed.
  • Figure 8 Comparison of the cytotoxic effects of wild type LT- ⁇ l/ ⁇ 2 and a LT- ⁇ (D50N)1/JS2 mutant on growth of: (a) mouse WEHI 164 cells, and (b) a human colon carcinoma tumor line HT29. Growth was quantitated after 3 days by measuring the optical density (OD 550) of reacted MTT, which is proportional to cell number.
  • Figure 9 The structure of the alpha carbon backbone of LT- ⁇ , illustrating the relatively few amino acid residues involved in trimerization. Those residues critical to the formation of a trimeric structure are highligh ed.
  • Figure 10 The amino acid sequences of CD40L, FasL and TNF C-terminal extracellular domains altered to drive trimerization with either wild type LT- ⁇ (for LT- ⁇ chimeras) or with wild type LT- ⁇ (for LT- ⁇ chimeras) .
  • Underlined residues represent sequences from LT- ⁇ or LT- ⁇ subunit association domains, respectively.
  • apoptosis refers to a process of programmed cell death.
  • association refers to a physically detectable condition of proximity between a portion of one ligand subunit with a portion of the same or a different ligand subunit wherein the juxtaposition is energetically favored by electrostatic, van der Waals or covalent interactions. A substantial disruption of the association between subunits is one which can be detected by a variety of methods.
  • association sequence and “association domain” both refer to a region (or portion thereof) of a LT polypeptide which drives the association between itself and other LT subunit association sequences to form the core scaffold structure of a LT multimeric ligand complex.
  • LT association domains typically comprise a ⁇ -sandwich structure and typically self-assemble into a trimeric scaffold structure.
  • backbone and “scaffold” interchangeably refer to the internal ⁇ -sandwich structure formed between multiple LT monomers oligomerizing through their subunit association domains.
  • ⁇ -pleated sheet refers to a sheetlike secondary structure assumed by portions of a polypeptide chain, the sheet held together by hydrogen bonds.
  • ⁇ -sandwich refers to a structure comprising two antiparallel ⁇ -pleated sheets with a "jelly-roll” or Greek key topology (Jones et al. , 1989; Eck et al. , 1992) .
  • complex refers to one monomeric polypeptide subunit associated with at least one other polypeptide subunit.
  • like subunits When subunits of the same type (“like subunits") associate, a “homomeric complex” is formed. When one or more like subunits associate with at least one different type of subunit, a “heteromeric complex” is formed.
  • the subunits can associate through electrostatic, van der Waals, or covalent interactions.
  • cytokine refers to a protein released by one cell type or population which acts on at least one other cell type or population to mediate intercellular signalling. Cytokine receptors bind cytokines and can trigger signalling events within the cell.
  • the TNF family of ligands are one set of many proteins that fall within the generic class of cytokines.
  • Other cytokines include hormones, growth factors, inductive factors, stimulating factors, inhibiting factors, interleukins, integrins, interferons and other polypeptide factors .
  • lymphotoxin- ⁇ refers to a member of the TNF-related cytokine family which is produced by activated T cells.
  • the original lymphotoxin- ⁇ (LT- ⁇ , previously called TNF- ⁇ ) and a newer member, lymphotoxin- ⁇ (LT- ⁇ ) comprise a system of secreted and membrane-anchored regulatory molecules involved in immunoregulation and host defense.
  • LT subunits typically form homotrimers or mixed heterotrimers.
  • LT- ⁇ biological activity is defined as: 1) immunological cross-reactivity with an antibody directed against at least one epitope of the corresponding native subunit or complex of subunits; or 2) the ability of the subunit or complex of subunits to compete for ligand binding sites on a LT-specific receptor such as TNF-R or LT- ⁇ -R; or 3) the ability to stimulate an immune regulatory response or cytotoxic activity qualitatively in common with a native LT subunit or complex.
  • LT- ⁇ / ⁇ heteromeric complex refers to an association between at least one LT- ⁇ subunit and at least one LT- ⁇ subunit.
  • the LT- ⁇ / ⁇ heteromeric complex has no more than two adjacent subunits comprising a binding site for a single receptor molecule.
  • the complex has the stoichiometry LT- ⁇ l/ ⁇ 2 or LT- ⁇ 2/ ⁇ l, and includes soluble, altered and chimeric forms thereof.
  • Soluble LT heteromeric complexes lack a transmembrane domain and can be secreted by an appropriate host cell which has been engineered to express LT- ⁇ and/or LT- ⁇ subunits. Examples of soluble LT heteromeric complexes are described in applicants ' co-pending international application (PCT/US93/11669, published January 9, 1992 as WO 94/13808) .
  • LT heterotrimeric complex refers to a LT heteromeric complex having three subunits, at least one of which has a portion of a LT subunit association domain or a portion of a LT receptor binding domain (TNF-R or LT- ⁇ -R) .
  • An "altered” or “modified LT heteromeric (or heterotrimeric) complex” is a multimeric ligand whose scaffold comprises more than one type of LT or LT chimeric subunit and in which at least one region of at least one of the LT or LT chimeric subunits has been modified, typically by mutation, to alter the ultimate receptor binding characteristics of the LT heteromeric complex.
  • LT chimeric heteromer
  • chimeric heterotrimer chimeric heterotrimer
  • chimeric ligand all refer to a heteromeric ligand comprising subunits each having a LT or LT-like subunit association domain which drives heteromer formation, and having an appropriate number of subunits with altered receptor binding domains to change the ultimate receptor binding characteristics of the chimeric heteromer.
  • the altered receptor binding domain may be taken from another TNF-like ligand receptor binding domain and grafted onto a polypeptide having a LT association domain.
  • a LT subunit association domain may be grafted onto a TNF-like ligand polypeptide having a TNF-like receptor binding domain.
  • Receptor binding domains or LT subunit association domains may also be remodeled or re- engineered by appropriate mutagenesis based on sequence and structural comparisons, and knowledge about which residues are critical for receptor binding and for subunit association, respectively.
  • LT heteromeric (or heterotrimeric) inhibitor refers to a LT heteromeric complex, a modified LT heteromeric complex or a chimeric LT heteromeric complex which can specifically bind to a TNF or TNF-like receptor but which cannot induce multiple molecules of that receptor to aggregate on the cell surface which normally triggers receptor signalling.
  • ligand binding domain refers to the portion or portions of a LT-, TNF- or TNF-like- receptor which is involved in specific recognition of and interaction with a LT, TNF or TNF-like ligand.
  • ligand refers to a ligand molecule (which may comprise multiple subunits) which can bind specifically to only a single receptor molecule with high affinity at one time, i.e., a ligand with only one functional receptor binding domain.
  • a "multivalent ligand” has more than one functional receptor binding domains and is thus capable of binding to and potentially clustering multiple receptor molecules.
  • receptor signalling refers to all molecular reactions associated with the activation of a particular receptor pathway and subsequent molecular reactions which result therefrom.
  • a “type I leader sequence” is an amino- ter inal portion of a eukaryotic protein which serves as a signal to direct the protein to the endoplasmic reticular (ER) membrane and often through the entire secretion pathway.
  • the leader sequence is usually cleaved off by a signal peptidase in the ER membrane.
  • a “signal sequence” is the functional equivalent of a eukaryotic type I leader sequence in prokaryotic hosts, and directs the translocation of proteins into or across lipid bilayer membranes of a bacterium.
  • mutation refers to a change made in the specific sequence of amino acids of a polypeptide, or in the specific nucleic acid sequences which encode those amino acids. Mutations can alter a DNA, RNA or protein molecule at a single base or amino acid position, or at multiple adjacent or non-adjacent positions. Mutations can be transitions or transversions of a single base, or deletions, insertions, inversions or translocations of nucleic acid sequences between regions of the same nucleic acid molecule or between different nucleic acid molecules. Amino acid mutations can similarly be directed to a single position of the polypeptide chain, heterologous sequences can be inserted, or deletions or rearrangements of the amino acid sequence can be made.
  • receptor cross-linking or "receptor clustering” refer to the physical aggregation of multiple adjacent receptor molecules in the plane of the cell surface membrane. Receptor clustering can act as a trigger, mediated by the intracellular domain(s) of the clustered and activated receptors, which starts a cascade of signalling events within the cell.
  • receptor binding domain and
  • receptor binding loop refer to the region or regions of a monomeric subunit comprising part of the receptor binding site of an oligomeric ligand containing that subunit, which contributes to or is capable of conferring receptor binding specificity. Residues critical for receptor binding are often found in a loop structure displayed from a central core as determined by three dimensional sequence modeling and on crystal structure analyses of various TNF family ligands.
  • the term "TNF-related ligand” refers to a ligand which may be classified as a member of the TNF family of ligands based on certain sequence conservation and on certain structural homologies which are conserved among family members.
  • TNF (ligand) homology region refers to amino acid residues located in the primary amino acid sequences of TNF family ligands which are conserved and which serve to identify TNF ligand family members.
  • the conserved homology regions appear to contribute to the formation of a three dimensional " ⁇ - sandwich" structure comprising two antiparallel ⁇ - pleated sheets.
  • TNF TNF-related ligands
  • LT- ⁇ and LT- ⁇ -- are only about 50% homologous at the amino acid level.
  • Localized sequence comparisons between the TNF ligand family reveal several regions of homology comprising conserved amino acid residues which serve as hallmark features for identifying TNF-related ligands.
  • TNF ligand homology regions are restricted to about 150 amino acid residues in the C-terminal portion of the proteins. These regions appear to form a ⁇ - sandwich structure from two anti-parallel ⁇ -pleated sheets (a classic viral "jelly-roll” motif; Jones et al., Nature. 338, pp. 225-28 (1989)) .
  • the ⁇ -sandwich is thus a structural motif common to the TNF ligands.
  • TNF and LT- ⁇ wedge-shaped monomer subunits associate by packing about a three-fold axis of symmetry to form a compact conical trimer in which the face of one subunit contacts the edge of an adjacent subunit.
  • the TNF homology regions in TNF and LT- ⁇ localize to the internal interfaces between adjacent interacting subunits of the trimeric ligand.
  • the ability to trimerize is encoded in these residues which line the contact points between subunits.
  • These internal residues define a scaffold structure upon which the external residues that contact a specific receptor are displayed within subunit clefts.
  • TNF ligand family members The most conserved amino acid regions among the other TNF ligands also fall within stretches of ⁇ - sandwich structures, and thus are likely to be analogous subunit association sequences .
  • a sequence alignment of the extracellular portions of five TNF ligand family members is shown in Figure 1. Residues known to be involved in TNF and LT- ⁇ trimerization (subunit association sequences) are underlined. Structural models show that the CD40L sequence can form an energetically favorable scaffold ⁇ -sheet structure like TNF and LT- ⁇ subunits. It is expected that many TNF ligand family members, and especially the more related TNF, LT- ⁇ , LT- ⁇ , CD40L and FasL ligands can assume similar structures.
  • the trimeric structures which assemble from these subunits may also be conserved.
  • the subunits of most TNF ligands do not randomly form mixed multimers.
  • specific sequences within the conserved subunit association domains must guide ⁇ -sandwich structures to preferentially self- associate into a homotrimeric scaffold.
  • LT- ⁇ and LT- ⁇ subunits are exceptions. Each can form homotrimers and mixed heterotrimers.
  • the LT- ⁇ and LT- ⁇ subunit association domains comprise specific residues which permit association between both heterologous and homologous subunits.
  • Intrinsic to the propensity for LT subunits to trimerize is their ability to form multivalent active ligands.
  • One active form is a soluble trimer consisting of three LT- ⁇ subunits.
  • the unique molecular environment of the cleft formed between adjacent LT- ⁇ subunits in a LT- ⁇ 3 trimer accounts for TNF-R receptor binding specificity (Zhang et al. , JL. Biol. Chem.. 267, pp. 24069-75 (1992); Banner et al. , Cell. 73, pp. 431-45 (1993) .
  • Another multivalent form (found in trace amounts in the membrane) consists of a trimer of two ⁇ subunits and one ⁇ subunit (LT- ⁇ 2/ ⁇ l) .
  • LT- ⁇ 2/ ⁇ l ⁇ subunits
  • LT- ⁇ 2/ ⁇ l ⁇ subunits
  • LT- ⁇ 2/ ⁇ l ⁇ subunits
  • LT- ⁇ 2/ ⁇ l ⁇ subunits
  • LT- ⁇ 2/ ⁇ l ⁇ subunits
  • TNF ligands responsible for mediating ligand-induced receptor activation by clustering multiple adjacent receptor molecules on the cell surface.
  • three, free TNF receptors can bind to LT- ⁇ 3.
  • Each TNF receptor binds to the ⁇ : ⁇ cleft between adjacent LT- ⁇ subunits.
  • Receptor clustering triggers signalling by the intracellular portion of the clustered receptors, which can cascade into multiple signals involving downstream effector molecules that participate in subsequent events associated with the receptor signalling pathway.
  • the internal scaffold structure which forms from trimerized LT subunit association domains can be exploited in various ways to make heteromeric trimers that have only one receptor binding site (i.e. are monovalent ligands) for a particular receptor.
  • a trimer with only one receptor binding site e.g. a LT- ⁇ 2/ ⁇ l heterotrimer in which the preferred receptor binding site lies in the one cleft between adjacent ⁇ : ⁇ subunits
  • the present invention covers all forms of LT heteromers that complex between subunit association domain ⁇ -sandwich structures present in LT- ⁇ and LT- ⁇ monomer subunits. Attached to this LT trimeric scaffold can be the original LT- ⁇ or LT- ⁇ sequences
  • mutations can be made by substitution, deletion or insertion of amino acid sequences, and can be of three forms: those that convert heteromeric clefts into inactive clefts; those that alter but do not inactivate receptor binding in heteromeric clefts; and those that convert entire LT- ⁇ / ⁇ or LT- ⁇ / ⁇ clefts into new clefts that will bind a different receptor (see below) .
  • LT subunit association sequences can be introduced into related TNF ligand subunit molecules to construct chimeric subunits which comprise a heterologous receptor binding domain and a LT subunit association domain.
  • LT chimeric heterotrimers assembled from a wild type LT subunit and two LT chimeric subunits are essentially monovalent and can bind only one heterologous TNF-like receptor molecule with high affinity.
  • the present invention also covers LT chimeric heterotrimers which can inhibit clustering and signalling by the corresponding heterologous receptor.
  • LT- ⁇ lacks a transmembrane domain and is localized to the cell surface through interaction with at least one membrane-bound LT- ⁇ subunit.
  • Membrane-bound (surface) LT- ⁇ / ⁇ heteromeric complexes have predominantly a LT- ⁇ l/ ⁇ 2 stoichiometry.
  • LT- ⁇ as a cell membrane protein binds LT- ⁇ during synthesis, thus "targeting" the LT- ⁇ to the cell membrane.
  • LT- ⁇ In the absence of LT- ⁇ , LT- ⁇ is secreted into the extracellular medium.
  • LT subunits normally assemble into complexes inside the cell prior to protein export into the membrane. Once LT- ⁇ subunits are inserted into the membrane, they do not form stable complexes with secreted LT- ⁇ . Thus if the membrane- bound form of a LT- ⁇ / ⁇ heteromeric complex is desired, it is preferable to co-express the desired LT- ⁇ and LT- ⁇ subunits within the same cell.
  • the surface LT- ⁇ / ⁇ heteromeric complex can be reconstructed by co-transfection of host cells with both the LT- ⁇ and LT- ⁇ genes. Surf ce LT complexes cannot be observed on stable cell lines which express either LT gene alone. However, if the host cell normally produces large amounts of LT- ⁇ (e.g. RPMI 1788 cells; see below), then transfection with a LT- ⁇ gene which encodes the desired LT- ⁇ polypeptide should be sufficient to generate LT- ⁇ / ⁇ complexes comprising non- recombinant LT- ⁇ subunits.
  • LT- ⁇ e.g. RPMI 1788 cells
  • LT- ⁇ and LT- ⁇ polypeptides in a number of eukaryotic expression systems leads to their assembly and export as active ligand (Crowe et al., J. Immunol. Methods. 168, 79-89 (1994)) .
  • Host systems that can be used include but are not limited to CHO cells, COS cells, B cells including myelomas, baculovirus-infected insect cells and yeast.
  • the LT- ⁇ subunit of the LT heteromeric complexes of this invention can be selected from lymphotoxin- ⁇ , native human or animal lymphotoxin- ⁇ , recombinant lymphotoxin- ⁇ , soluble lymphotoxin- ⁇ , secreted lymphotoxin- ⁇ , lymphotoxin- ⁇ muteins having LT- ⁇ biological activity, or lymphotoxin- ⁇ fragments of any of the above having LT- ⁇ biological activity.
  • the LT- ⁇ polypeptide of the LT heteromeric complexes of this invention can be any soluble form of the molecule including active fragments thereof which can be produced in eukaryotic expression systems, wherein the natural LT- ⁇ leader sequence will be cleaved off.
  • fusions of the mature LT- ⁇ sequence with a heterologous signal sequence can be used to maximize the secretion of LT- ⁇ / ⁇ heteromeric complexes in other host systems.
  • Signals are chosen based on the intended host cell, and may include bacterial, yeast, mammalian and viral sequences.
  • the native signal, or the vascular cell adhesion molecule-1 (VCAM-1) signal sequence is suitable for use in mammalian expression systems.
  • the LT- ⁇ polypeptides of the LT heteromeric complexes of this invention can also be fused to polypeptides having a prolonged plasma half-life such as immunoglobulin chains or fragments thereof.
  • Plasma proteins which may be used to enhance plasma half-life include serum albumin, immunoglobulins, apolipo- proteins, and transferrin. Polyethylene glycol (PEG) attachment may stabilize the polypeptide and lower its immunogenicity.
  • the LT- ⁇ fusion protein is not significantly immunogenic in the subject to be treated and the plasma protein does not cause undesirable side effects in subjects due to its normal biological activity.
  • Human LT- ⁇ is glycosylated on N and 0 residues, and depending on the source, exhibits considerable sugar-based microheterogeneity.
  • the oligosaccharide composition of the particular LT- ⁇ chosen to form the LT complex may affect in vivo clearance rates (Fukushima et al . , Arch. Biochem.
  • LT- ⁇ can be purified from a B lymphoblastoid line RPMI 1788, which constitutively secretes LT- ⁇ and which can be induced to secrete higher levels by treating with the phorbol ester PMA (Aggarwal et al., J. Biol. Chem.. 259, pp. 686-91 (1984)).
  • the cloned human LT- ⁇ gene can be used to recombinantly produce the LT- ⁇ polypeptides of the LT heteromeric complexes of this invention in different host systems including bacteria (Schoenfeld et al., J. Biol. Chem.. 266, pp. 3863-69 (1991)); baculovirus- infected insect cells (Crowe et al., J. Immunol.
  • LT- ⁇ gene which encode polypeptide fragments having LT- ⁇ biological activity can be evaluated using routine screening assays .
  • Useful screening assays for LT- ⁇ biological activity include competitive inhibition assays with native LT- ⁇ bound to TNF-R, or measuring either directly or indirectly by inhibition the ability of the LT- ⁇ to induce cytotoxicity of tumor cells in assays known to the art.
  • LT- ⁇ fragments are assembled into heteromeric complexes with LT- ⁇ and the complexes assayed for LT- ⁇ / ⁇ biological activity by competitive inhibition with LT- ⁇ / ⁇ bound to LT- ⁇ -R, or for their ability to induce cytotoxicity of tumor cells in the assays disclosed herein.
  • Lymphotoxin- ⁇ also referred to as p33, has been identified on the surface of T lymphocytes, T cell lines, B cell lines and lymphokine-activated killer cells.
  • LT- ⁇ is the subject of applicants' co-pending international applications PCT/US91/04588, published January 9, 1992 as WO 92/00329; and PCT/US93/11669, published June 23, 1994 as WO 94/13808, which are herein incorporated by reference.
  • LT- ⁇ The LT- ⁇ gene encodes a polypeptide of 240- 244 amino acids (Browning et al. , Cell. 72, pp. 847-56 (1993)) .
  • LT- ⁇ is a type II membrane protein with a short N-terminal cytoplasmic domain followed by a membrane anchoring domain of 30 hydrophobic amino acids. It has a single N-linked glycosylation site and has only one cysteine residue which does not appear to be involved in intersubunit disulfide bond formation.
  • the LT- ⁇ subunits comprising the LT heteromeric complexes of the present invention can be selected from lymphotoxin- ⁇ , native human or animal lymphotoxin- ⁇ , recombinant lymphotoxin- ⁇ , soluble lymphotoxin- ⁇ , secreted lymphotoxin- ⁇ , lymphotoxin- ⁇ muteins having LT- ⁇ biological activity, or lymphotoxin- ⁇ fragments of any of the above having LT- ⁇ biological activity.
  • the LT- ⁇ polypeptides can also be modified to increase their solubility or plasma half-life using the same methods. Likewise, portions of the LT- ⁇ gene which encode polypeptide fragments having LT- ⁇ biological activity can be evaluated using routine screening assays as discussed for LT- ⁇ .
  • LT- ⁇ and LT- ⁇ proteins to form either LT- ⁇ l/ ⁇ 2 or LT- ⁇ 2/ ⁇ l heterotrimers.
  • LT- ⁇ is normally a secreted protein, but is sequestered at the cell surface by binding to surface LT- ⁇ .
  • LT- ⁇ / ⁇ trimers can be prepared in a soluble form.
  • Soluble (non-membrane-bound) LT- ⁇ / ⁇ heteromeric complexes comprise LT- ⁇ subunits which have been changed from a membrane-bound to a soluble form. These complexes are described in detail in applicants ' co-pending international application (PCT/US93/11669, published January 9, 1992 as WO 94/13808) .
  • Soluble LT- ⁇ peptides are defined by the amino acid sequence of lymphotoxin- ⁇ wherein the sequence is cleaved at any point between the end of the transmembrane region (i.e. at about amino acid #44) and the first TNF homology region (i.e. at amino acid #88) according to the numbering system of Browning et al., Cell. 72, pp. 847- 56 (1993).
  • Soluble LT- ⁇ polypeptides may be produced by truncating the N-terminus of LT- ⁇ to remove the cytoplasmic tail and transmembrane region (Crowe et al., Science. 264, pp. 707-710 (1994)).
  • the transmembrane domain may be inactivated by deletion, or by substitution of the normally hydrophobic amino acid residues which comprise a transmembrane domain with hydrophilic ones . In either case, a substantially hydrophilic hydropathy profile is created which will reduce lipid affinity and improve aqueous solubility. Deletion of the transmembrane domain is preferred over substitution with hydrophilic amino acid residues because it avoids introducing potentially immunogenic epitopes.
  • the deleted or inactivated transmembrane domain may be replaced with or attached to a type I leader sequence (e.g. the VCAM-1 leader) such that the protein is secreted beginning with a sequence anywhere from between val40 to pro88.
  • Soluble LT- ⁇ polypeptides may include any number of well-known leader sequences at the N-terminus. Such a sequence would allow the peptides to be expressed and targeted to the secretion pathway in a eukaryotic system. See, e.g., Ernst et al., United States Patent No. 5,082,783 (1992) .
  • Soluble LT- ⁇ / ⁇ heteromeric complexes may be produced by co-transfecting a suitable host cell with DNA encoding LT- ⁇ and soluble LT- ⁇ (Crowe et al. , J. Immunol. Methods. 168, pp. 79-89 (1994)) . Soluble LT- ⁇ secreted in the absence of LT- ⁇ is highly oligomerized. However, when co-expressed with LT- ⁇ , a 70 kDa trimeric-like structure is formed which contains both proteins.
  • soluble LT- ⁇ l/ ⁇ 2 heteromeric complexes by transfecting a cell line which normally expresses only LT- ⁇ (such as the RPMI 1788 cells discussed above) with a gene encoding a soluble LT- ⁇ polypeptide.
  • LT- ⁇ and LT- ⁇ polypeptides may be separately synthesized, denatured using mild detergents, mixed together and renatured by removing the detergent to form mixed LT heteromeric complexes which can be separated (see below) .
  • LT- ⁇ / ⁇ heteromers to bind to different receptors can be exploited as a method for purifying a specific LT heteromeric form from a mixture of heteromers of differing compositions.
  • Homogeneous receptors are immobilized onto a matrix and preferably, are packed into a column.
  • a mixture containing heteromeric ligands is then mixed with, or passed over a column of the affinity matrix under conditions wherein the ligands bind to the matrix- linked receptors.
  • Heteromeric ligands of a specific composition can then be purified by differentially eluting ligands with lower receptor binding constants with a gradual or step-wise change in the conditions that affect ligand-receptor interaction (i.e., salt and pH) .
  • LT- ⁇ 2/ ⁇ l heteromeric complexes are separated from co-expressed complexes comprising a different subunit stoichiometry by chromatography using TNF and LT- ⁇ receptors as affinity purification reagents.
  • TNF receptors only bind within ⁇ / ⁇ clefts of LT complexes.
  • the LT- ⁇ receptor binds with high affinity to ⁇ / ⁇ clefts, and with lower affinity to ⁇ / ⁇ clefts of heteromeric LT- ⁇ / ⁇ complexes.
  • LT- ⁇ 3 and LT- ⁇ 2/ ⁇ l will bind to TNF-R.
  • the LT- ⁇ -R can also bind LT- ⁇ 2/ ⁇ l trimers (within the ⁇ / ⁇ clefts) but cannot bind LT- ⁇ 3.
  • the LT- ⁇ -R (but not TNF-R) binds LT- ⁇ l/ ⁇ 2 and LT- ⁇ n (the exact composition of such preparation is unknown, however, they are large aggregates) .
  • the receptor affinity reagents can be prepared as either a soluble extracellular domain (see for example Loetscher et al. , J. Biol. Chem.. 266, pp. 18324-29 (1991)), or as chimeric proteins with the extracellular ligand binding domain coupled to an immunoglobulin Fc domain (Loetscher et al. , J. Biol. Chem.. 266, pp. 18324-29 (1991); Crowe et al. , Science. 264, pp. 707-710 (1994)) .
  • Receptors are coupled to affinity matrices by chemical cross-linking using routine procedures.
  • LT- ⁇ 2/ ⁇ l ligand can be purified ( Figure 2) .
  • a supernatant from an appropriate expression system co-expressing both LT- ⁇ and the truncated LT- ⁇ form is passed over a TNF-R column.
  • the bound LT- ⁇ 3 and LT- ⁇ 2/ ⁇ l trimers are eluted via classical methods such as chaotrophe or pH change.
  • the eluate solution is neutralized or the chaotrophe removed, and the solution is then applied to a LT- ⁇ -R column. Only the LT- ⁇ 2/ ⁇ l binds to the LT- ⁇ -R and the LT- ⁇ 3 flows through the column.
  • Soluble LT- ⁇ l/ ⁇ 2 heteromeric complexes are separated from co-expression complexes comprising a different subunit stoichiometry by chromatography using TNF and LT- ⁇ receptors as selective affinity purification reagents, as described above.
  • the LT- ⁇ l/ ⁇ 2 ligand can be purified using receptors and immuno- affinity chromatography.
  • a supernatant from an appropriate expression system co- expressing both LT- ⁇ and the truncated LT- ⁇ form is passed over a TNF-R column.
  • the TNF-R will bind LT- ⁇ 3 and LT- ⁇ 2/ ⁇ l trimers.
  • the flow through from the TNF-R column will contain LT- ⁇ (n) and LT- ⁇ l/ ⁇ 2 (Example 3) .
  • LT- ⁇ -containing forms (LT- ⁇ (n) , LT- ⁇ l/ ⁇ 2 and LT- ⁇ 2/ ⁇ l) are bound to and eluted from a LT- ⁇ -R column using classical methods such as chaotrophe or pH change.
  • LT- ⁇ 3 flows through this column) .
  • the eluate is neutralized or the chaotrophe removed, and the eluate is then passed over a TNF-R column, which binds only to the LT- ⁇ 2/ ⁇ l trimers.
  • the flow through of this column will contain LT- ⁇ (n) and LT- ⁇ l/ ⁇ 2 trimers.
  • purified LT- ⁇ l/ ⁇ 2 trimers can be separated from LT- ⁇ by subsequent gel filtration and/or ion exchange chromatographic procedures known to the art.
  • Various combinations of affinity columns which can be used are diagrammed in Figure 2.
  • the receptor purification schemes outlined above can be modified to purify variously altered forms of the LT heteromeric complexes by coupling a different receptor to a column matrix. For example, if the ⁇ / ⁇ cleft of LT- ⁇ l/ ⁇ 2 is converted to a CD40R binding cleft by mutagenesis of residues involved in receptor binding, a CD40 receptor column could be used as a step to purify the chimeric LT/CD40 heterotrimers. A CD40 receptor column could also be used to purify chimeric LT/CD40 heteromeric complexes assembled from CD40 subunits mutated in their subunit association domains to induce trimerization with LT- ⁇ or LT- ⁇ subunits.
  • the various heteromeric trimers i.e., LT- ⁇ l/ ⁇ 2, LT- ⁇ 2/ ⁇ l and mutant and chimeric forms thereof
  • different mutant and chimeric forms of LT- ⁇ / ⁇ heteromeric complexes can be separated and purified by a variety of conventional chromatographic means well known to those of skill in the art. It may also be preferable to combine a series of conventional purification schemes with one or more of the immunoaffinity purification steps described above.
  • LT and other ligand subunits separated by gel electrophoresis may be detected by radiolabelling the proteins prior to electrophoresis, or by staining the gel after electrophoresis with dyes that bind polypeptides (such as coomassie blue) and performing densitometry tracing.
  • the proteins in the gel may also be blotted onto a membrane and probed.
  • the probes may be enzymatically, fluorescently or radioactively- labelled anti-subunit antibodies, or another antibody which recognizes an immunological tag (such as the myc epitope) incorporated into one or more of the ligand subunits ("Western blot") . All techniques are well known to the art.
  • the LT- ⁇ / ⁇ heteromeric complexes purified according to the methods set forth in Examples 2 and 3 using the combination of immunoaffinity columns as in Figure 2 (right side) were characterized (Example 4)by SDS PAGE analysis.
  • the purified LT- ⁇ / ⁇ heterotrimers were also individually analyzed by C4 reverse phase HPLC, and the relative ratios of LT- ⁇ and LT- ⁇ in each fraction is shown in Figure 3.
  • LT- ⁇ / ⁇ heteromeric complexes using a TSK 3000 HPLC resin in a phosphate buffered saline buffer (Figure 4a, Example 4) confirmed that the LT heteromeric complexes behave as trimers of about 50-60kDa molecular weight.
  • Ion exchange chromatographic analyses of the purified LT heteromeric complexes ( Figure 4b; Example 4) further confirmed the results of the experiments described above, and indicate that cross- contamination between different LT heteromeric forms is no greater than 1-5% after affinity purification. Taken together, these experiments identify the LT heteromeric complexes made according to the purification procedures described in Examples 2 and 3 as LT- ⁇ l/ ⁇ 2 and LT- ⁇ 2/ ⁇ l heterotrimers.
  • the LT heteromeric complexes of this invention are capable of inhibiting receptor signalling by binding to a cell surface receptor molecule without mediating clustering of adjacent receptors. To qualify as an effective inhibitor, the LT heteromeric complexes must bind to the selected receptor with an affinity high enough to compete with endogenous multivalent ligands for binding sites on the receptor.
  • ligand- receptor binding assays are performed.
  • the strength of the binding between a receptor and ligand can be measured using an enzyme- linked immunoadsorption assay (ELISA) , a radio- immunoassay (RIA) , or other such immunodetection methods which are techniques well known in the art.
  • ELISA enzyme- linked immunoadsorption assay
  • RIA radio- immunoassay
  • the ligand-receptor binding interaction may also be measured with the BiacoreTM instrument which exploits plasmon resonance detection (Zhou et al. ,
  • the BiacoreTM technology allows one to bind receptor to a gold surface and to flow ligand over it. Plasmon resonance detection gives direct quantitation of the amount of mass bound to the surface in real time. This technique yields both on and off rate constants and thus a ligand-receptor dissociation constant and affinity constant can be directly determined.
  • LT heteromeric inhibitor made from wild type, mutated, altered or chimeric LT and TNF-related ligand subunits.
  • FIG. 5a characterizes the binding profiles of the various LT heterotrimer forms to p55 TNF-R and to LT- ⁇ -R ( Figure 5b) as a function of time.
  • Figure 5a shows that LT- ⁇ 3 and LT- ⁇ 2/ ⁇ l -- but not LT- ⁇ l/ ⁇ 2 — bind specifically to TNF-R.
  • Figure 5b shows that both LT- ⁇ 2/ ⁇ l and LT- ⁇ l/ ⁇ 2 bind LT- ⁇ -R, but that LT- ⁇ 2/ ⁇ l heterotrimers bind with a lower affinity.
  • LT- ⁇ / ⁇ Heterotrimers Can Inhibit Receptor Signalling
  • a LT heteromeric complex can bind to a selected target receptor and preferably, that it can compete with endogenous ligands for receptor binding sites
  • an assay to monitor the activity of that selected receptor once it is bound to the LT heteromeric ligand must be performed. Assays known to be reliable indicators of signalling by the selected receptor will, of course, be preferred. In any event, at least one activity associated with the activation of the selected receptor should be measured to assess the ability of the potential LT heteromeric inhibitor, when bound to the selected receptor, to inhibit receptor signalling. Assays which monitor the activity of related but non-selected receptors by the addition of a putative LT heteromeric inhibitor can also be performed.
  • Such assays are useful in detecting co- activated or co-inhibited receptors which are stimulated or inhibited by the LT heteromeric inhibitor preparation.
  • a stimulatory or inhibitory effect on the non-selected receptor might be due to cross-reaction of the purified LT heteromeric ligand with the non- selected receptor. Alternatively, these effects might be due to low levels of a contaminating LT heteromeric form(s) in the purified preparation which can activate or inhibit the non-selected receptor.
  • the soluble LT- ⁇ 2/ ⁇ l heterotrimer is claimed herein as an inhibitor of the p55 TNF-R and p75 TNF-R.
  • LT- ⁇ 2/ ⁇ l can bind within its one ⁇ / ⁇ cleft to a TNF receptor, but not within its two ⁇ / ⁇ clefts. Because this LT- ⁇ 2/ ⁇ l heterotrimer is monovalent for TNF-R, it cannot cluster or "cross-link" multiple surface TNF-R molecules and thus it blocks normal TNF-R signalling activity.
  • Purified LT- ⁇ 2/ ⁇ l can inhibit the action of TNF or LT- ⁇ in a number of culture systems.
  • the mouse L929 cell can be killed by TNF or LT- ⁇ in either short term cytolytic assays or in longer term growth inhibition assays (Example 6) .
  • the short term cytolytic assay actually constitutes the standard analytical tool for assessing the biological activity of these two cytokines. These assays have been previously described (Browning et al. , J. Immunol.. 143, pp. 1859-67 (1989)) .
  • Figure 6a shows that LT- ⁇ 2/ ⁇ l can block TNF action in mouse L929 cytolytic assays and in related growth inhibition assays using the human tumor lines Mel80 ( Figure 6b) and HT29 ( Figure 6c) .
  • interferon-a is included since it acts synergistically with TNF to inhibit cell growth.
  • the LT- ⁇ l/ ⁇ 2 form which cannot bind to the p55 TNF-R, is inactive in blocking TNF activity (not shown) .
  • These experiments show that purified LT- ⁇ 2/ ⁇ l can compete with natural TNF for binding to TNF-R, thereby inhibiting TNF-R signalling activity.
  • These assays are considered representative of physiological TNF activity.
  • LT- ⁇ 2/ ⁇ l was able to block the TNF-induced increase in VCAM and ELAM on human umbilical vein endothelial cell surfaces, which is a reliable assay for the inflammatory activity of TNF (P. Vassalli, Annu. Rev. Immunol.. 10, pp. 441-52 (1992)) .
  • Figure 7 the ability of a soluble LT- ⁇ -R
  • LT- ⁇ -R-Fc to bind to LT molecules displayed on the surface of a T cell hybridoma
  • Example 7 shows that purified LT- ⁇ l/ ⁇ 2 can block the binding of soluble LT- ⁇ -Rs to a T cell hybridoma displaying surface LT- ⁇ / ⁇ complexes .
  • This result demonstrates that the soluble LT- ⁇ l/ ⁇ 2 molecules of this invention can effectively compete with natural cell surface LT molecules for binding to the LT- ⁇ -R. Its ability to compete with cell surface LT in this assay supports the notion that soluble LT- ⁇ l/ ⁇ 2, or mutated or altered forms thereof (see below) , will be useful as a therapeutic agent to inhibit signalling by the LT- ⁇ -R.
  • LT heteromeric inhibitors may exhibit cross-reactivity or background binding activity to other known or unknown receptors. This can interfere with the desired result of inhibiting certain signalling pathways.
  • certain LT- ⁇ / ⁇ heteromers may mediate non-productive monovalent interactions or may abnormally bridge different receptor molecules resulting in "confused receptor aggregation" . This interaction with additional receptors may be reduced or eliminated by mutagenesis of exposed amino acid residues of an LT subunit which lie within a receptor binding cleft not involved in binding to and inhibiting the selected receptor.
  • the LT- ⁇ subunit may be mutagenized to eliminate receptor binding activity in one of the LT- ⁇ / ⁇ clefts of a LT- ⁇ 2/ ⁇ l heterotrimeric inhibitor. Mutations in either LT- ⁇ or LT- ⁇ subunits in the soluble LT- ⁇ l/ ⁇ 2 or LT- ⁇ 2/ ⁇ l complexes could increase the specificity of inhibitors assembled from them. Similarly, mutagenesis of exposed LT subunit residues can also be useful in eliminating residual receptor binding activity due to low levels of alternate trimeric forms contaminating a purified LT heterotrimer preparation.
  • LT- ⁇ l/ ⁇ 2 preparations typically exhibited some trace cytotoxic activity when assayed using the WEHI 164 or L929 cytolytic assays (Example 6) .
  • This activity could be blocked by anti-LT- ⁇ monoclonal antibodies (mAbs) or by soluble p55 TNF-R, suggesting that it was caused by residual levels of LT- ⁇ 3 trimeric forms in the LT- ⁇ l/ ⁇ 2 trimer preparations.
  • mAbs monoclonal antibodies
  • soluble p55 TNF-R suggesting that it was caused by residual levels of LT- ⁇ 3 trimeric forms in the LT- ⁇ l/ ⁇ 2 trimer preparations.
  • either directed or random mutagenesis using available techniques can be performed on amino acid residues predicted to be exposed within the cleft between two subunits.
  • Mutagenized proteins are then assembled into trimers either by expressing and isolating individual subunits and mixing them in vitro, or by co-expression of subunit genes in vivo.
  • Heteromeric ligands are purified according to procedures described in Examples 2 and 3, and the purified forms functionally screened and selected based on altered receptor binding characteristics using standard immunological techniques and the procedures set forth in Examples 5-7.
  • LT- ⁇ 2/ ⁇ l can bind to and inhibit aggregation of TNF-R, as shown above.
  • LT- ⁇ 2/ ⁇ l heterotrimers also bind LT- ⁇ -R within the ⁇ / ⁇ clefts ( Figure 5b) , and thus can also compete for binding between LT- ⁇ -R and cell surface LT molecules in the 11-23 cell assay described above.
  • LT- ⁇ 2/ ⁇ l binds to LT- ⁇ -R with lower affinity that to p55 TNF-R.
  • p55 TNF-R binding can be reduced or eliminated by mutagenizing specific residues within the ⁇ / ⁇ cleft.
  • Modified LT- ⁇ 2/ ⁇ l heterotrimers comprising mutant LT- ⁇ subunits that no longer bind TNF-R would act as selective inhibitors of the LT- ⁇ -R signalling pathway. Mutations have been described in LT- ⁇ that eliminate the ability of LT- ⁇ 3 to trigger cell death in the mouse WEHI 164 line.
  • One example is the "D50N mutation" which changes Asp50 to Asn50 and eliminates LT- ⁇ 3 binding to TNF-R (Goh and Porter, Protein En ⁇ .. 4, p. 385 (1991); Van et al . , Protein En ⁇ .. 7, p. 5 (1994) ) .
  • FIG. 8a shows the growth inhibition activity of wild-type LT- ⁇ l/ ⁇ 2 and mutant LT- (D50N) 1/S2 trimers on WEHI 164 cells. Normal preparations of LT- ⁇ 3 trimers show 50% growth inhibition at 1-10 pg/ml, and wild-type LT- ⁇ l/ ⁇ 2 typically retain 0.1-1% LT- ⁇ -like activity.
  • Mutations can also be introduced in LT subunits to influence the relative binding affinity of a LT heteromer for one receptor type over another. For example, single amino acid replacements have been made in the TNF ligand that limit its binding to either p55 TNF-R or p75 TNF-R but not both receptors (Van et al., Nature. 361, pp.266-69 (1993)) . It is likely that similar point mutations can be engineered into the LT- ⁇ subunit gene to restrict the binding of a LT heteromer comprising that modified LT- ⁇ subunit to one of the two TNF receptors. In this case, a modified LT- ⁇ 2/ ⁇ l heterotrimer with the restricted LT- ⁇ form would be a selective inhibitor of only one receptor form. As these receptors mediate different signals, the modified LT- ⁇ 2/ ⁇ l heterotrimer would be more selective in its inhibitory properties, and would likely be more useful clinically.
  • the TNF-R binding domain could be grafted onto the LT- ⁇ (or the LT- ⁇ ) subunit association domain (described below) , and such point mutations that specifically destroy one or the other form of TNF-R could be incorporated into these modified LT subunits.
  • Chimeric TNF/LT heterotrimers assembled from the modified LT subunits would be selective inhibitors of only one form of TNF-R. Soluble LT- ⁇ l/ ⁇ 2 heterotrimers bind to the
  • the LT- ⁇ l/ ⁇ 2 trimer can also be used as an inhibitor of LT- ⁇ -R signalling. Mutations in the LT- ⁇ subunit of the trimer may be required to eliminate binding of other as yet unidentified receptors to LT- ⁇ /LT- ⁇ clefts. As these interactions are likely to involve binding modes similar to those involved in p55 TNF-R, mutations in LT- ⁇ that are known to eliminate p55 TNF-R binding are reasonable candidates.
  • LT- ⁇ l/ ⁇ 2 and LT- ⁇ 2/ ⁇ l heterotrimers By incorporating such mutations into the LT- ⁇ l/ ⁇ 2 and LT- ⁇ 2/ ⁇ l heterotrimers, one could enhance their selectivity and reduce any undesirable side effects caused by background levels of promiscuous receptor binding.
  • LT- ⁇ l/ ⁇ 2 that are already known to affect LT- ⁇ activity and then ask whether a LT- ⁇ l/ ⁇ 2 molecule assembled with such an LT- ⁇ mutation retained activity using cytotoxicity or growth inhibition assays such as those described in Example 6.
  • Mutations that eliminated activity while retaining LT- ⁇ -R binding (Example 5) would be chosen as putative therapeutic LT heteromeric inhibitors.
  • the ability to specifically modulate receptor binding enhances the utility of LT- ⁇ /
  • This invention also relates to the use of sequences of LT- ⁇ and LT- ⁇ which, when inserted in the appropriate context, allow the molecule to associate with similar sequences of another LT subunit.
  • association sequences when spaced with amino acids stretches of an appropriate length, fold into a TNF-like structure capable of associating with other TNF-like structures to form heteromeric trimers.
  • the TNF-like association sequences behave as a structural and functional domain, and can thus be inserted as a separable unit into a molecule to enable it to trimerize.
  • the subsequent trimer represents a unique structural scaffold onto which new domains of sequence can be built.
  • the structure of the ⁇ -carbon backbone of LT- ⁇ with the residues critical for trimer formation highlighted is shown in Figure 9.
  • CD40/LT Chimeric Inhibitors A heteromeric molecule capable of binding to the CD40 receptor (CD40R) may consist of one LT- ⁇ and two CD40L/LT- ⁇ chimeric subunits.
  • the chimeric subunits should possess sufficient portions of the internal scaffold region to allow association of the CD40L/LT- ⁇ chimeric subunits with LT- ⁇ , and should also retain as much CD40L sequence as possible to retain maximal CD40 receptor binding cleft sequences and to minimize the amount of potentially antigenic chimeric sequences formed.
  • a CD40L-LT chimera may consist of either the "association sequences" of LT- ⁇ engrafted onto the CD40L structure or the ligand binding domain of CD40L engrafted onto the LT- ⁇ core association sequences.
  • a heteromeric molecule capable of binding to CD40R may consist of one LT- ⁇ and two CD40L/LT- ⁇ chimeric subunits.
  • a LT- ⁇ l/ ⁇ 2 or LT- ⁇ 2/ ⁇ l molecule may be converted into a CD40 pathway inhibitor.
  • the receptor binding domain of TNF family ligands is separated from the transmembrane domain by a "stalk" region that has a variable length depending on the family member.
  • the portion of the sequence of the stalk regions for the CD40 ligand is shown in Figure 10. Shorter or longer stalks than those shown in Figure 10 may also be compatible.
  • Sequence 1 ( Figure 10) may be constructed in an appropriate vector and the protein co-expressed from that vector along with the wild type soluble LT- ⁇ protein as described in Example 1. Co-expression can be performed in a suitable system such as the baculovirus/insect cell system described herein, or in another suitable system such as in animal cells or yeasts such as Picchia cells.
  • Chimeric proteins are passed over a CD40 receptor affinity column (made using the same procedure as the LT- ⁇ -R affinity column in Example 2, except soluble CD40R is coupled to the column) , and those proteins possessing a CD40R binding domain are isolated.
  • Complexes possessing a LT- ⁇ subunit are then purified using an anti-LT- ⁇ monoclonal affinity column resulting in a preparation of CD40L/LT- ⁇ chimera/LT- ⁇ complexed at a 1:2 and 2 :1 ratios. These forms can be separated using another purification step such as ion exchange chromatography.
  • the binding properties of the chimeric complexes to CD40 receptor may then be ascertained using BIAcoreTM technology as described in Example 5.
  • Improvements in the ability of the CD40/LT- ⁇ chimeric subunit to trimerize with LT- ⁇ subunits can be made at this stage.
  • additional amino acids in the CD40 subunit association domain can be changed individually or in groups to increase or decrease further the match between those found in the LT- ⁇ subunit association domain.
  • Altered chimeric subunits are then complexed with LT- ⁇ subunits, and trimers of various compositions separated by affinity chromatography as described above. Stability of the altered (CD40L/LT- ⁇ ) 2/LT- ⁇ l chimeric trimers can be assessed by storing the preparations for extended periods of time and periodically analyzing the samples by ion exchange chromatography to determine the purity of the trimers.
  • sequences of the CD40/LT chimeric subunit required to optimize expression, heterotrimer assembly and stability may be determined by making several CD40 forms having increasing lengths of the stalk regions shown in Figure 10. If too few of the CD40 stalk sequences are used, proper folding of this region into a ⁇ -sandwich structure may be interfered with, thus reducing efficient heterotrimer formation. If these sequences are too long, increased proteolysis could result.
  • the improved ability of altered chimeric CD40/LT- ⁇ subunits to trimerize with LT- ⁇ subunits may be monitored in parallel with the increase or decrease in CD40 receptor binding activity caused by the length of the CD40 sequences and by additional amino acid alterations.
  • CD40L/LT- ⁇ chimeric subunit Figure 10; Seq 2
  • Chimeric (CD40L/LT- ⁇ ) 2 /LT- ⁇ l heterotrimers that are able to bind to a CD40 Receptor affinity matrix and to an anti-LT- ⁇ monoclonal antibody affinity resin can be isolated, characterized and optimized as described above.
  • Additional mutations may also be incorporated into the LT- ⁇ or LT- ⁇ receptor binding domains of the wild type LT and the chimeric CD40/LT subunits to reduce any residual background binding to TNF-R or LT- ⁇ -R by (CD40L/LT- ⁇ )2/LT- ⁇ l or (CD40L/LT- ⁇ )2/LT- ⁇ l heterotrimers, as described in Example 8.
  • Fas/LT Chimeric Inhibitors A heteromeric FasL/LT- ⁇ or FasL/LT- ⁇ subunit may be made using sequences shown in Figure 10 (Seq 3 and Seq 4) .
  • the chimeric heterotrimers having (FasL/LT- ⁇ )2/LT- ⁇ l and (FasL/LT- ⁇ )2/LT- ⁇ l stoichiometries may be constructed, tested and optimized.
  • CD40/LT chimeras several C-terminal stalk sequences will also be compatible with the expression of a functional molecule.
  • the desired characteristics can be optimized by constructing chimeric FasL/LT subunits with varying lengths of the C-terminal stalk domains shown in Figure 10.
  • a heteromeric TNF/LT- ⁇ or TNF/LT- ⁇ subunit may be constructed using the sequences shown in Figure 10 (Seq 5 and Seq 6) . Following the same steps outlined above, the chimeric heterotrimers having (TNF/LT- ⁇ )2/LT- ⁇ l and (TNF/LT- ⁇ )2/LT- ⁇ l stoichiometries may be constructed, tested and optimized. Also as described above, several C- terminal stalk sequences will also be compatible with the expression of a functional molecule. The desired characteristics can be optimized by constructing chimeric TNF/LT subunits with varying lengths of the C- terminal stalk domains shown in Figure 10.
  • LT- ⁇ and LT- ⁇ sequences that must be included in a molecule to force the correct heteromeric trimer formation may vary slightly in length for each specific application. By techniques routine to molecular biology, these sequences may be altered by one or two amino acids on each end to form the optimum structure for a particular chimeric heterotrimer. Likewise, any single amino acid in this scaffold region may not be absolutely crucial to the structure and such minor changes do not constitute unique molecules according to this invention. Appropriate functional assays for ligand binding activity will provide the fine tuning enabling one to determine which exact amino acid residues are optimal.
  • LT- ⁇ / (X) complexed with LT- ⁇ in a LT- ⁇ l/ ⁇ 2 trimer would now bind receptor X in the LT- ⁇ (X)/LT- ⁇ (X) cleft. As only one such cleft exists per molecule, this chimeric trimer inhibits receptor X cross-linking and subsequent signalling.
  • Receptor binding domains of TNF-like ligands are domains of protein sequence that loop off of the domains which form the TNF-like association sequences.
  • the receptor binding domains comprise specific amino acid sequences that confer the high degree of ligand- receptor binding specificity. Accordingly, exchange of the LT receptor binding loop with one from another ligand of the TNF family would convert the resulting trimeric ligand into one that now binds that different receptor.
  • residues comprising a receptor binding domain of a TNF-like ligand have been identified by analysis of crystal or co-crystal structures or by structure-function analyses using random and directed mutagenesis, these sequences can be used to replace the corresponding domain of a LT- ⁇ or LT- ⁇ subunit to construct hybrid or chimeric LT- ⁇ / ⁇ trimers with new receptor binding properties.
  • These chimeric LT- ⁇ / ⁇ trimers will function as inhibitors of signalling by the new receptor to which the chimeric trimer binds to.
  • LT trimeric scaffold similar loops from other ligands can be readily spliced onto either the LT- ⁇ or LT- ⁇ scaffolds creating --when complexed with the appropriate LT- ⁇ or LT- ⁇ pair --monovalent ligands for these other receptors.
  • the receptor binding loop of the LT- ⁇ molecule is replaced by the corresponding region from CD40L, which mediates CD40L- CD40 binding.
  • This hybrid subunit would be capable of forming a LT- ⁇ l/ ⁇ 2 heterotrimer having a single CD40 binding site in the LT- ⁇ /LT- ⁇ cleft.
  • the Fas ligand is closely related to LT- ⁇ and LT- ⁇ and represents an easy extension of the principles outlined above. Similar LT chimeric subunits could potentially be constructed for any TNF-related ligand subunit.
  • the chimeric trimer can be expressed and tested directly for binding affinity using BiacoreTM technology. Once a good receptor binding site has been created, the chimeric LT- ⁇ subunit can be expressed with LT- ⁇ and the inhibitor heteromeric form isolated. In this way one can optimize the receptor binding site without the need to co-express two genes and perform the purification procedures of distinct heteromeric forms. Alternatively, inhibitory activity can be measured in a functional assay by measuring the ability of the chimeric inhibitor to block the pathway concerned.
  • LT/CD40L chimeric construct For CD40 signalling, one could monitor the ability of the LT/CD40L chimeric construct to induce the death of a cell line containing CD40/TNF chimeric receptors (Hess et al. , Eur. J. Immunol.. 25, pp. 80-86 (1995)) .
  • Fas-dependent cell killing assays Itoh et al. , cell. 66, pp. 233-43 (1991)
  • binding and inhibitory assays can be used to systematically vary the exact splice points used to form a LT-chimeric subunit. In this way, fine tuning can maximize the effectiveness of LT- chimeric subunits as inhibitors of receptor signalling.
  • compositions of this invention will be administered at an effective dose to treat the particular clinical condition addressed. Determination of a preferred pharmaceutical formulation and a therapeutically efficient dose regiment for a given application is well within the skill of the art taking into consideration, for example, the condition and weight of the patient, the extent of desired treatment and the tolerance of the patient for the treatment. Typically, humans can tolerate up to 100-200 ⁇ g/m 2 of TNF before serious toxicity is manifested (Schiller et al. , Cancer Res.. 51, pp. 1651-58 (1991)) .
  • mice In mice, dosages in the range of 1-5 ⁇ g/mouse/day given with 5x10 4 units of recombinant human IFN- ⁇ caused human primary tumor regression (Balkwill et al . , CIBA Foundation Symposium (1987); Havell et al. , J. Exp. Med.. 167, pp. 1067-85 (1988)) . Based on the relative effectiveness of TNF and LT- ⁇ l/ ⁇ 2 in the HT29 cytolytic assays, approximately 5-25 ⁇ g/mouse/day of LT- ⁇ l/ ⁇ 2 will provide a therapeutic dose range.
  • LT- ⁇ l/ ⁇ 2 and LT- ⁇ 2/ ⁇ l dosages of at least 1 mg/m 2 will be required.
  • Similar dosages of various altered and chimeric LT heteromeric inhibitors are expected to be suitable starting points for optimizing treatment doses and schedules according to methods known to those of skill in the art.
  • Administration of the LT- ⁇ / ⁇ heteromeric inhibitors of this invention may be accomplished using any of the conventionally accepted modes of administration of agents which exhibit anti- tumor activity.
  • compositions used in these therapies may also be in a variety of forms. These include, for example, solid, semi-solid and liquid dosage forms such as tablets, pills, powders, liquid solutions or suspensions, suppositories, and injectable and infusible solutions.
  • the preferred form depends on the intended mode of administration and therapeutic application. Modes of administration may include oral, parenteral, subcutaneous, intravenous, intralesional or topical administration.
  • the LT- ⁇ / ⁇ heteromeric inhibitors may, for example, be placed into sterile, isotonic formulations with or without cofactors which stimulate uptake or stability.
  • the formulation is preferably liquid, or may be lyophilized powder.
  • the LT heteromeric inhibitors may be diluted with a formulation buffer comprising 5.0 mg/ml citric acid monohydrate, 2.7 mg/ml trisodium citrate, 41 mg/ml mannitol, 1 mg/ml glycine and 1 mg/ml polysorbate 20.
  • This solution can be lyophilized, stored under refrigeration and reconstituted prior to administration with sterile Water-For-Injection (USP) .
  • USP Water-For-Injection
  • compositions also will preferably include conventional pharmaceutically acceptable carriers well known in the art (see for example Remington's
  • Such pharmaceutically acceptable carriers may include other medicinal agents, carriers, genetic carriers, adjuvants, excipients, etc., such as human serum albumin or plasma preparations.
  • the compositions are preferably in the form of a unit dose and will usually be administered one or more times a day.
  • compositions of this invention may also be administered using microspheres, liposomes, other microparticulate delivery systems or sustained release formulations placed in, near, or otherwise in communication with affected tissues or the bloodstream.
  • sustained release carriers include semipermeable polymer matrices in the form of shaped articles such as suppositories or microcapsules.
  • Implantable or microcapsular sustained release matrices include polylactides (U.S. Patent No. 3,773,319; EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al. , Biopolymers. 22, pp.
  • Liposomes containing LT heteromeric inhibitors can be prepared by well-known methods (see, e.g. DE 3,218,121; Epstein et al. , Proc. Natl. Acad. Sci. U.S.A.. 82, pp. 3688-92 (1985); Hwang et al. , Proc. Natl. Acad. Sci. U.S.A.. 77, pp. 4030-34 (1980); U.S. Patent Nos. 4,485,045 and 4,544,545) . Ordinarily the liposomes are of the small (about 200-800
  • the LT heteromeric complexes of this invention may also be attached to liposomes which may optionally contain other therapeutic agents directed to the particular treatment being performed. Attachment of LT heteromeric complexes to liposomes may be accomplished by any known cross-linking agent such as heterobifunctional cross-linking agents that have been widely used to couple toxins or chemotherapeutic agents to antibodies for targeted delivery.
  • Conjugation to liposomes can also be accomplished using the carbohydrate-directed cross-linking reagent 4- (4- maleimidophenyl) butyric acid hydrazide (MPBH) (Duzgunes et al. , J. Cell. Biochem. Abst. Suppl. 16E 77 (1992) .
  • MPBH 4- (4- maleimidophenyl) butyric acid hydrazide
  • TNF and LT- ⁇ are cytokines with an extraordinary range of activities mediated by TNF-R activation.
  • the utility of the LT- ⁇ 2/ ⁇ l trimeric molecules stems from their potential to effectively inhibit TNF-R receptor signalling.
  • the soluble LT- ⁇ 2/ ⁇ l trimers will be useful as therapeutic agents in treating clinical conditions known to be improved by TNF inhibition (Beutler, B. , Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. New York: Raven Press (1994)) .
  • Such clinical conditions include septic shock, autoimmune diseases such as diabetes, rheumatoid arthritis, inflammatory bowel disease, and HIV proliferation.
  • the soluble LT- ⁇ 2/ ⁇ l inhibitors of this invention comprise human protein sequences, and thus immune recognition by individuals treated with these complexes should be minimal.
  • the complexes of this invention should be amenable to long term therapeutic administration and should be especially suitable for treating chronic autoimmune conditions.
  • LT- ⁇ l/ ⁇ 2 inhibitors stems from their potential to effectively inhibit LT- ⁇ -R receptor signalling.
  • disruption of the LT- ⁇ gene leads to aberrant peripheral lymphoid organ development (De Togni et al. , Science. 264, pp. 703-7 (1994) ) .
  • This phenotype is associated with loss of LT- ⁇ -R signalling because no similar phenotypes have been observed by modulating TNF-R activity.
  • signalling through the CD40 pathway is inhibited using chimeric LT heterotrimers that have been converted into monovalent CD40R-specific ligands.
  • Signalling through the CD40 pathway induces B cells, upon stimulation by helper T cells, to undergo immunoglobulin (Ig) maturation and secretion. Immature B cells begin by making only surface IgM. Upon signals from an activated helper T cell, B cells proliferate and mature into memory and antibody-secreting cells. The signal responsible for this maturation process is initiated by CD40R signalling.
  • the LT/CD40 chimeric ligands of the present invention could be useful both for modulating certain Ig maturation steps during B cell development, and for inhibiting the onset or controlling the severity of certain autoimmune diseases in humans.
  • One preferred embodiment of this invention is directed to chimeric CD40/LT subunits which comprise LT subunit association sequences inserted or engineered into CD40 ligand polypeptides which have CD40 receptor binding domains.
  • the LT subunit association sequences can drive complex formation between LT and CD40/LT chimeric subunits.
  • the sequence conservation within TNF homology regions of the TNF ligand family, and the apparent conservation of the ⁇ -sandwich structures which can form from the TNF homology domains permits the design of CD40, Fas, TNF, and other such chimeric LT ligands. It is thus envisioned that similar chimeric LT complexes may be made by applying the techniques described herein to other ligand polypeptides belonging to the TNF family. Coupled with the powerful immunological techniques which are currently available, such as those described herein, functional chimeric molecules can be selected from a mixture of various chimeric heteromeric complexes and can be identified and purified in a straight-forward manner.
  • Another preferred embodiment of this invention is directed to the use of CD40L sequences to alter receptor binding properties of LT- ⁇ / ⁇ trimers to inhibit the CD40 pathway.
  • this embodiment as well as the one described above, is directed to making CD40/LT chimeric ligands
  • the invention as envisioned is in no way limited to this one example. Any region of a ligand which is capable of conferring receptor binding affinity and which can be inserted onto the LT- ⁇ / ⁇ trimers scaffold in such a way that it alters or converts receptor binding characteristics of a resulting heteromeric ligand is anticipated to fall within the scope of this invention.
  • Fas signalling involves inhibiting signalling through the Fas pathway using chimeric Fas/LT heterotrimers that have been converted into monovalent Fas-specific ligands.
  • signalling through the Fas pathway has pleiotropic effects.
  • Activated Fas can kill cells by apoptosis.
  • Apoptosis is responsible for negative thymocyte selection during normal T cell maturation, as well as for mature T cell-mediated cytotoxicity by killer T cells.
  • Cell killing mechanism is a major component of graft rejection and therefore inhibitors of the Fas pathway may be useful in reducing tissue rejection following organ transplantation.
  • Fas signalling is also involved in the T cell apoptosis observed during HIV disease (Katsikis et al. , J. Exp. Med.. 181, pp. 2029-36 (1995)) .
  • Inhibitors of the Fas pathway may also be useful in blocking HIV-induced lymphocyte depletion.
  • Fas signalling is involved in apoptosis of chronically- activated mature T cells, and suggest a role for Fas signalling in peripheral tolerance (Russel and Wang, Eur. J. Immunol .. 23, pp. 2379-82 (1993)) .
  • Fas signalling by monovalent Fas/LT chimeric ligands could be useful in inhibiting deleterious B cell proliferation.
  • the pleiotropic nature of Fas signalling is a feature of several of the other TNF family members, including CD30 and both TNF receptors.
  • the specific effect of ligand-induced receptor signalling including cell death by apoptosis or necrosis, or cell proliferation, is dependent on the cell type, its stage of differentiation, its transformation status and on other environmental factors (Smith et al. , Cell. 76, pp. 959-62 (1994)). It is thus expected that new effects of signalling through various TNF and TNF-like receptors will continue to be found.
  • the chimeric LT heterotrimeric complexes of the present invention will be useful as inhibitors of these signalling pathways by applying the methods taught herein.
  • the following are examples which illustrate the LT heteromeric inhibitors of this invention and the methods used to characterize them. These examples should not be construed as limiting: the examples are included for purposes of illustration and the present invention is limited only by the claims.
  • Recombinant baculovirus was prepared encoding either full length LT- ⁇ or a secreted form of LT- ⁇ as described (Crowe et al. , J. Immunol. Methods. 168, pp. 79-89 (1994)) .
  • High fiveTM insect cells were inoculated at a density of 2xl0 5 cells/ml into 7.2 liters of SF 900-11 (Gibco) media without serum. The culture reached 1.8xl0 6 cells/ml 48 hours later and was infected with 150 ml (3xl0 8 PFU/ml) LT- ⁇ and 300 ml of LT- ⁇ baculovirus stocks. Two days later, the culture was harvested and the cell debris was removed by centrifugation. After addition of 1 mM EDTA and 150 uM PMSF (final concentration) , the clarified supernatant was concentrated 10 fold by ultrafiltration using a
  • S1YM10 (Amicon) spiral cartridge.
  • the concentrate was divided into six 120 ml portions and aliqouts were stored at -70°C prior to purification.
  • Receptor affinity reagents can be prepared as either a soluble extracellular domain (see for example
  • Receptors are coupled to affinity matrices by chemical cross-linking using routine procedures.
  • the extracellular domain of LT- ⁇ -R up to the transmembrane region was amplified by PCR from a cDNA clone using primers that incorporated Notl and Sail restriction enzyme sites on the 5' and 3' ends, respectively (Browning et al. , J. Immunol.. 154, pp. 33-46 (1995)) .
  • the amplified product was cut with Notl and Sail, purified and ligated into Notl-linearized vector pMDR901 along with a Sall-Notl fragment encoding the Fc region of human IgGl.
  • the resultant vector contained the dihydrofolate reductase gene and the LT- ⁇ -R-Fc chimera driven by separate promoters.
  • the vector was electroporated into CHO dhfr " cells and methotrexate-resistant clones were isolated as per standard procedures.
  • the LT- ⁇ -R-Fc is secreted into the medium and an ELISA assay was used to select for cell lines producing the highest level of the chimeric protein.
  • a high-producing cell line was grown to large numbers and conditioned medium collected.
  • the pure protein was isolated by Protein A sepharose fast flow affinity chromatography.
  • the column was washed sequentially with 5 column volumes of phosphate buffered saline (PBS), PBS with 0.5 M NaCl and PBS and then eluted with 25 mM sodium phosphate, 100 mM NaCl, pH 2.8. Elution fractions were immediately neutralized with 1/20 volume of 0.5 M sodium phosphate, pH 8.6 and stored on ice. Fractions containing protein were identified by absorbance at 280 nm, pooled and the elution pools from the six columns were analyzed by SDS-PAGE stained with coomassie brilliant blue.
  • PBS phosphate buffered saline
  • the p55 TNF-R-FC column eluate contained purified LT- ⁇ 2/ ⁇ l and LT- ⁇ and the mix was further purified by affinity purification over a LT- ⁇ -R-Fc column.
  • the LT- ⁇ flows through this column and the LT- ⁇ 2/ ⁇ l is retained. Elution as described above yielded pure LT- ⁇ 2/ ⁇ l.
  • a portion (120 ml) of the S1Y10 concentrate was passed over two sequential p55 TNF-R-Fc column as described above and the flow through which was now depleted of LT- ⁇ and LT- ⁇ 2/ ⁇ l was further passed over a LT- ⁇ -R-Fc column.
  • the column was washed with 5 volumes each of PBS, PBS with 0.5 M NaCl and PBS and eluted with 25 mM sodium phosphate, 100 mM NaCl, pH 3.5. Elution fractions were immediately neutralized with 1/20 volume of 0.5 M sodium phosphate, pH 8.6 and stored on ice.
  • the stoichiometry of LT- ⁇ to LT- ⁇ contained in the purified LT- ⁇ l/ ⁇ 2 and LT- ⁇ 2/ ⁇ l fractions was evaluated either by densitometry tracing of the coomassie stained gels or by peak height analysis of the two peaks obtained following resolution on C4 reverse phase HPLC.
  • the purified fractions were sized by gel exclusion chromatography to assess whether trimers were formed and whether aggregates were present.
  • a TSK G2000 sw xl column was used at a flow rate of 0.5 ml/min to size separate a BioRad gel filtration protein standard, and the three different LT trimers: LT- ⁇ 3, LT- ⁇ 2/ ⁇ l and LT ⁇ l/ ⁇ 2.
  • the plasmon resonance detection method as embodied by the BIAcoreTM instrument provides a powerful method for the determination of the strength of binding interactions between two proteins (Zhou et al., Biochemistry. 32, pp. 8193-98 (1993); Faegerstram and O'Shannessy, "Surface plasmon resonance detection in affinity technologies". In Handbook of Affinity Chromatography. pp. 229-52, Marcel Dekker, Inc., New York (1993)) .
  • a soluble receptor e.g. p55TNF-R-immunoglobulin Fc fusion protein, is bound to the "chip" supplied by the manufacturer using various known chemistries. In this case, the
  • N-hydroxy-succinimide based linkage system was employed according to the specifications of the manufacturer.
  • the coupled chip was washed in the instrument, and soluble ligand at various concentrations between 0.1 and 100 ⁇ g/ml was flowed over the chip. Bound protein is directly indicated by the instrument.
  • Figure 5a shows an example of the sensorgrams depicting the binding of LT- ⁇ l/ ⁇ 2 and LT- ⁇ 2/ ⁇ l to the LT- ⁇ receptor.
  • BIAcoreTM technology allows one to bind receptor to a gold surface and ligand is flowed over it. Plasmon resonance detection gives direct quantitation of the amount of mass bound to the surface in real time.
  • FIG. 5b shows an example of the sensorgrams depicting the binding of LT- ⁇ and LT- ⁇ 2/ ⁇ l to the p55 TNF-R.
  • the equilibrium binding constant is the ratio of the on to off binding rates.
  • Mouse L929 cells can be killed by TNF or LT- ⁇ 3 in either short term cytolytic assays or in longer term growth inhibition assays. These assays have been described (Browning et al. , J. Immunol.. 143, pp. 1859-67 (1989)). Purified LT- ⁇ 2/ ⁇ l can inhibit the cytolytic activity of TNF or LT- ⁇ 3 in a number of culture systems.
  • Figure 6a shows a typical competition assay showing that LT- ⁇ 2/ ⁇ l can effectively compete with TNF in the mouse L929 cytolytic assay.
  • the HT29 human adenocarcinoma cytolytic assay has been previously described (Browning and Ribolini, J. Immunol..
  • This protocol can also be used to measure growth inhibition of other tumor lines, such as the Me 180 cells used here.
  • Interferon-a was included in tumor cell assays since it acts synergistically with TNF to inhibit tumor cell growth.
  • serial dilutions of LT- ⁇ 2/ ⁇ l were prepared in 0.05 ml in 96 well plates and 5000 trypsinized HT29 cells added in 0.05 ml of media containing 80 U/ml (anti-viral units) of human IFN- ⁇ .
  • HT29-14 cells which are from a subclone of the original ATCC-derived HT29 line that is more homogeneous give the same results as the original ATCC- derived HT29 line) .
  • mitochondrial reduction of the dye MTT was measured as follows: 10 ul of MTT was added and after 3 hours, the reduced dye dissolved with 0.09 ml of isopropanol with lOmM HCl, and the O.D. measured at 550 nm. The number of viable cells is proportional to the absorbance.
  • soluble receptor By mixing these cells with varying concentrations of the soluble ligand and then adding soluble receptor (LT- ⁇ -R-Fc) , one can measure how well the soluble ligand can compete with the cell surface ligand for binding to the soluble receptor.
  • soluble receptor LT- ⁇ -R-Fc
  • FACS analysis Crowe et al., Science. 264, pp. 707-710 (1994) following the binding of soluble LT- ⁇ -R-Fc chimera to LT- ⁇ l/ ⁇ 2 on the surface of PMA-activated 11-23 cells.
  • This assay is a useful tool in the design of altered LT- ⁇ l/ ⁇ 2 forms that retain LT- ⁇ receptor binding activity, yet lack the ability to induce receptor signalling.
  • Figure 7 shows the ability of various amounts of soluble ligand to block receptor binding using the assay described above. A reduction in the mean fluorescence value was used to calculate percent inhibition. Molecular weights of 90 kDa for the dimeric receptor-Fc construct and 65kDa for the trimeric ligand were employed to calculate molarities. Binding competition was carried out for 30 minutes on ice followed by washing of the cells and probing of bound human Fc with a secondary antibody.
  • an Asp50 to Asn50 mutation was introduced into the LT- ⁇ construct using "U.S.E.” mutagenesis (Pharmacia) .
  • a recombinant baculovirus capable of expressing the "LT- ⁇ (D50N)" mutant was prepared and insect cells were co-infected with the LT- ⁇ (D50N) and wild-type LT- ⁇ viruses.
  • the insect cell supernatant was passed over a LT- ⁇ -R affinity column, and the bound fraction eluted as described in Example 3.
  • This fraction contained both LT- ⁇ (D50N) l/ ⁇ 2 and LT- ⁇ (D50N)2/ ⁇ l forms. These forms were separated from each other by ion exchange chromatography as described in Examples 2 and 3, yielding purified LT- ⁇ (D50N)1/S2 and LT- (D50N)2/ ⁇ l modified heterotrimers.
  • Figure 8a shows the growth inhibition activity of wild-type LT- ⁇ l/ ⁇ 2 and mutant LT- ⁇ (D50N) l/ ⁇ 2 trimers on WEHI 164 cells.
  • Normal preparations of LT- ⁇ 3 trimers show 50% growth inhibition at 1-10 pg/ml, and wild-type LT- ⁇ l/ ⁇ 2 preparations typically retain 0.1-1% of an LT- ⁇ -like activity.
  • the D50N mutation which abolishes activity of normal LT- ⁇ 3 on these cells, also eliminated the residual LT- ⁇ -like activity in the altered LT- ⁇ l/ ⁇ 2 preparation.
  • Figure 8b shows that the LT- ⁇ (D50N) 1/S2 altered heteromeric complex retains full specific activity in a WiDr cytotoxicity assay (performed as per the HT29 assay in Browning and Ribolini, J. Immunol.. 143, pp. 1859-67 (1989)), which measures signalling through the LT- ⁇ -R.
  • WiDr assay is described in applicants ' co-pending United States application Serial no. 08/378,968.
  • a series of tissue culture wells containing tumor cells such as WiDr cells are cultured for three to four days in media containing IFN- ⁇ and either wild type or the mutant LT- ⁇ (D50N) l/ ⁇ 2 heteromeric complex to be tested.
  • a vital dye stain which measures mitochondrial function (such as MTT) is added to the cell mixture and reacted for several hours, and then the optical density of the mixture in each well is quantitated at 550 nm wavelength light (OD 550) .
  • the OD 550 is proportional to the growth of tumor cells in the presence of the LT- ⁇ / ⁇ heteromeric complex.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

On décrit des complexes de lymphotoxines (LT), comprenant des sous-unités de lymphotoxines-α (LT-α) et de lymphotoxines-β (LT-β) et des versions qui en sont modifiées, complexes pouvant agir à titre d'inhibiteurs spécifiques des phénomènes biologiques induits par les ligands et les récepteurs propres à la famille des facteurs de nécrose tumorale (TNF). On décrit aussi des parties uniques des séquences protéiniques de LT-α et β, les 'domaines d'association propres à des sous-unités de LT', qui potentialisent l'assemblage de ces sous-unités en un ligand trimère actif. On décrit des monomères de ligands associés TNF et ayant subi une mutation de leurs domaines d'association respectifs de sous-unités, ce qui leur permet de former des complexes hétéromères avec des sous-unités de LT. Des ligands modifiés, qui ne présentent qu'un site fonctionnel de liaison à un récepteur par hétéromère, peuvent inhiber la signalisation provenant de ce récepteur. On décrit aussi des sous-unités mutantes et chimères deLT qui peuvent modifier les propriétés de liaison à un récepteur que présentent des complexes hétéromères assemblés à partir d'elles. On décrit aussi des polypeptides comprenant ces domaines d'association de sous-unités LT, des complexes hétéromères de LT qui inhibent la signalisation de récepteurs, des compositions pharmaceutiques comprenant ces inhibiteurs hétéromères propres aux LT, et des procédés de traitement impliquant l'utlisation de ces compositions pharmaceutiques.
PCT/US1996/009773 1995-06-07 1996-06-06 Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques WO1996040774A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU61663/96A AU6166396A (en) 1995-06-07 1996-06-06 Complexes of modified lymphotoxins as pharmaceutical prepara tions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47607495A 1995-06-07 1995-06-07
US08/476,074 1995-06-07

Publications (1)

Publication Number Publication Date
WO1996040774A1 true WO1996040774A1 (fr) 1996-12-19

Family

ID=23890401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009773 WO1996040774A1 (fr) 1995-06-07 1996-06-06 Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques

Country Status (2)

Country Link
AU (1) AU6166396A (fr)
WO (1) WO1996040774A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012964A3 (fr) * 1997-09-12 1999-05-27 Biogen Inc Kay, nouvelle proteine du systeme immunitaire
WO1999012965A3 (fr) * 1997-09-12 1999-06-03 Biogen Inc Nouveaux ligands de la famille des tnf
WO2001025277A1 (fr) * 1999-10-07 2001-04-12 Maxygen Aps Polypeptides antagonistes a chaine unique
EP1042343A4 (fr) * 1997-11-03 2001-08-16 Human Genome Sciences Inc Vegi, un inhibiteur de l'angiogenese et de la croissance tumorale
WO2002034780A3 (fr) * 2000-10-26 2002-07-11 Vlaams Interuniv Inst Biotech Procedes et moyens de deoligomerisation de molecules oligomeres
EP1100886A4 (fr) * 1998-08-07 2003-06-18 Human Genome Sciences Inc Facteur de necrose tumorale gamma
WO2007054658A1 (fr) * 2005-11-14 2007-05-18 King's College London Contrôle de réponses immunitaires

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000329A1 (fr) * 1990-06-27 1992-01-09 Biogen, Inc. Lymphotoxine de surface sous forme de complexe
WO1994013808A2 (fr) * 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXINE-β, COMPLEXES DE LYMPHOTOXINES-β, PREPARATIONS PHARMACEUTIQUES ET LEURS UTILISATIONS THERAPEUTIQUES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000329A1 (fr) * 1990-06-27 1992-01-09 Biogen, Inc. Lymphotoxine de surface sous forme de complexe
WO1994013808A2 (fr) * 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXINE-β, COMPLEXES DE LYMPHOTOXINES-β, PREPARATIONS PHARMACEUTIQUES ET LEURS UTILISATIONS THERAPEUTIQUES

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C. GOH ET AL.: "Aspartic acid 50 and tyrosine 108 are essential for receptor binding and cytotoxic activity of tumour necrosis factor beta (lymphotoxin).", PROTEIN ENGINEERING, vol. 4, no. 7, October 1991 (1991-10-01), OXFORD, GB, pages 785 - 791, XP002016899 *
J. BROWNING ET AL.: "Preparation and characterization of soluble recombinant heterotrimeric complexes of human lymphotoxins alpha and beta.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 15, 12 April 1996 (1996-04-12), BALTIMORE, MD, USA, pages 8618 - 8626, XP002016900 *
J. BROWNING ET AL.: "Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 183, no. 3, 1 March 1996 (1996-03-01), NEW YORK, NY, USA, pages 867 - 878, XP000608398 *
K. WARZOCHA ET AL.: "Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.", EUROPEAN CYTOKINE NETWORK, vol. 5, no. 6, November 1994 (1994-11-01), MONTROUGE, pages 83 - 96, XP000608365 *
P. CROWE ET AL.: "A lymphotoxin-beta-specific receptor.", SCIENCE, vol. 264, no. 5159, 29 April 1994 (1994-04-29), WASHINGTON, DC, USA, pages 707 - 710, XP002003806 *
P. CROWE ET AL.: "Production of soluble lymphotoxin (LT) alpha/beta mutein complexes using the baculovirus expression system.", THE FASEB JOURNAL, vol. 8, no. 4, 15 March 1994 (1994-03-15), BETHESDA, MD, USA, pages A509, XP002016898 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599719B2 (en) * 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
WO1999012964A3 (fr) * 1997-09-12 1999-05-27 Biogen Inc Kay, nouvelle proteine du systeme immunitaire
WO1999012965A3 (fr) * 1997-09-12 1999-06-03 Biogen Inc Nouveaux ligands de la famille des tnf
EA005411B1 (ru) * 1997-09-12 2005-02-24 Апотек Р Энд Д Са Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей
EP1042343A4 (fr) * 1997-11-03 2001-08-16 Human Genome Sciences Inc Vegi, un inhibiteur de l'angiogenese et de la croissance tumorale
EP1100886A4 (fr) * 1998-08-07 2003-06-18 Human Genome Sciences Inc Facteur de necrose tumorale gamma
WO2001025277A1 (fr) * 1999-10-07 2001-04-12 Maxygen Aps Polypeptides antagonistes a chaine unique
WO2002034780A3 (fr) * 2000-10-26 2002-07-11 Vlaams Interuniv Inst Biotech Procedes et moyens de deoligomerisation de molecules oligomeres
WO2007054658A1 (fr) * 2005-11-14 2007-05-18 King's College London Contrôle de réponses immunitaires

Also Published As

Publication number Publication date
AU6166396A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
Tanaka et al. Expression of the functional soluble form of human fas ligand in activated lymphocytes.
Rooney et al. The lymphotoxin-β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells
AU768475B2 (en) Interleukin 17-like receptor protein
JP4411330B2 (ja) 腫瘍壊死因子関連リガンド
Starling et al. Identification of amino acid residues important for ligand binding to Fas
US7695934B2 (en) Tumor necrosis factor related ligand
CA2210644A1 (fr) Ligands pour recepteurs de type eph
JP2002514079A (ja) キメラｏｐｇポリペプチド
JP2007039464A (ja) リンホトキシン−β、リンホトキシン−β複合体、それらの薬学的な調製物および治療への使用
AU678369B2 (en) TNF ligands
SK8552001A3 (en) A method for the high level expression of active lymphotoxin-'beta' receptor immunoglobulin chimeric proteins and their purification
KR19990063653A (ko) 케모킨 억제제
KR20010080073A (ko) 림포독소 베타 경로의 차단에 의한 바이러스-유도성 전신쇼크 및 호흡 장애의 반전
WO1996040774A1 (fr) Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques
EP2657252B1 (fr) Polypeptide modifié de récepteur 1 du facteur de nécrose tumorale humain ou fragment de celui-ci, et procédé de préparation associé
US9068019B2 (en) Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
US8895500B2 (en) Modified human tumor necrosis factor receptor-I polypeptide or fragment thereof, and method for preparing same
US7910321B2 (en) Methods of determining the level of human tumor necrosis factor receptor-like 2
AU2004212622C1 (en) A Tumor Necrosis Factor Related Ligand
KR20240053675A (ko) sBCMA 변이체 및 이의 FC 융합 단백질을 이용한 IgA, IgM 및/또는 IgG의 생산 감소 방법
MXPA01002677A (en) Interleukin 17-like receptor protein
IL103052A (en) Soluble interferon-alpha receptors,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载